Pennsylvania Developed COVID-19 Vaccine Candidate Expands Study in China

In COVID-19, Latest News by Precision Vaccinations

A biotechnology company announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. 
The Phase 2 clinical trial being conducted in China will enroll approximately 640 participants who are 18 years or older.
INOVIO and Advaccine Biopharmaceuticals Suzhou Co., Ltd. announced in a press release on December 10, 2020, the dosing regimen involves two vaccinations at 0 and 28 days, with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of Phase 2/3 clinical trial in the USA.

Read More